
    
      Patients will be evaluated monthly for one year.

      Participants will be assigned to one of two groups:

      Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection
      throughout the remainder of the study Group B will receive injections of ranibizumab on an as
      needed basis throughout the study

      You cannot take part in this study if:

        1. You are pregnant or intending to become pregnant in the next 12 months or are nursing an
           infant

        2. You are under the age of 18
    
  